Table 6.
Summary of published work about the development of mimetic EVs nanovesicles by bottom-up bio-nanotechnology, showing formulation of the vesicles, molecules for the surface functionalization and main physical characteristic (size).
Formulation | Preparation method | Conjugation strategy | Size | Protein for functionalization | Reference |
---|---|---|---|---|---|
PC:SM:Cho:DOGS-NTA (55:30:10:5) weight ratio For fluorescent labelling, 0.25% mole/mole DSPE-RhodB |
Thin-film hydration method (KCl 100 mM, HEPES 10 mM pH 7.0, EDTA 0.1 mM; KHE buffer) Filtered and degassed + extrusion over 200 nm membranes |
Ni2+-NTA headgroup functionalized lipid + histidine-tagged recombinant peptides 37°C, 30 min |
150–200 nm | APO2L/TRAIL-His10 | [102] |
PC:Cho:DSPE-PEG:DSPE-PEG-MAL (1:0.5:0.04:0.01) Molar ratio For fluorescent labelling, 1% of PC amount of DSPE-RhodB |
Thin-film hydration method (Hepes 25mM, NaCl 140mM; pH 7.4) Filtered and degassed + extrusion over 100 nm membranes |
Maleimide headgroup functionalized lipid + Traut’s reagent protein activation 1h RT 20/1 ratio |
100 nm | MHC class I peptide complexes and FAB regions against T-cell receptors (adhesion, early and late activation and survival) | [15] |
Micro-emulsion phase PC:CpEL (7:3, w/w) Micelle phase In 10:1 v/v DE:A DOPE:DC-Cho (4:1, w/w) In 1:2 v/v EtOH:DW |
Micro-emulsion and micelle combining method + sonication step for 3min | Carboxilic group from ChoS and amine group from protein EDC/NHS 4°C for 12 h |
82 nm | Monoclonal antibody against DEC205 antigen expressed on dendritic cells | [103] |